Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Citalopram SCHEMBL13235283 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL29494157 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| (R)-Citalopram SCHEMBL29414626 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL29358316 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL34948 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL946 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Escitalopram SCHEMBL522164 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL1118 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL21820669 | 0.99 | SLC6A4 (0.98) | SLC6A4SLC6A2HTR2CADRA1AHRH1 | |
| Citalopram SCHEMBL1286979 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2HTR2CADRA1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200149109-A1 | Method to Predict Response to Neuropsychiatric Drugs Using Variation in the Serotonin 7 Receptor (HTR7) Gene | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-05-14 | — | — | US | disclosed |
| EP-1670427-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1680121-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1670427-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |